Symptom control after different duration of triptorelin treatment following conservative surgery for deep infiltrating endometriosis: Post-hoc analysis of a multicentre, prospective, real-world study.
Medicine (Baltimore)
; 100(30): e26753, 2021 Jul 30.
Article
in En
| MEDLINE
| ID: mdl-34397719
ABSTRACT
ABSTRACT Triptorelin has been used after surgery in deep infiltrating endometriosis. This post-hoc analysis aimed to evaluate symptom control between patients receiving 1-3 triptorelin injections and those receiving 4-6 injections within 24âmonths of conservative surgery for deep infiltrating endometriosis, in the real-world.Included patients were divided into two groups (received up to 3âmonths injections in group A, 4-6 injections in group B) based on the numbers of triptorelin (Diphereline, 3.75 mg intramuscular injection once every 28âdays for up to 24âweeks) administration. Evolution in score of pain intensity at 3, 6, 9, 12, 18, and 24âmonths after primary triptorelin administration and symptom improvement/recurrence rates between two groups were compared. Symptoms of pain intensity were assessed using a visual analogue scale (VAS) with a range from 0 to 10âcm. An improvement in symptoms was defined as a reduction of at least 3âcm or 3 units from pre-surgery levels.156 patients in group A and 228 in group B. Pain symptom score (meanâ±âstandard deviation) diminished to a nadir at 3-months for group A and 6-months for group B; at 6-months nadir scores were significantly lower in group B (0.9â±â1.7 vs 0.4â±â1.2 respectively, Pâ=â.002). No significant difference for pain symptom scores between both groups at 24-months (Pâ=â.269). The 6-month and 24-month cumulative improvement rates of pain (80.6% vs 89.8%, Pâ=â.014 and 82.6% vs 90.7%, Pâ=â.025) and gastro-intestinal symptoms (61.0% vs 80.8%, Pâ=â.022 and 61.0% vs 83.3%, Pâ=â.008) were significantly higher in group B, whereas there was no significant difference in rates of menstrual disorders and urinary symptoms. There is no significant difference for 12-months and 24-months cumulative recurrence rates of total symptoms between both groups (11.3% vs 13.8%, Pâ=â.568 and 16.1% vs 26.0%, Pâ=â.094).In women with deep infiltrating endometriosis, longer treatment with triptorelin following conservative surgery was associated with a decrease in symptom intensity and greater improvement of pain symptoms in the short-term and greater improvement of gastro-intestinal symptoms in the long-term.Trial registration number ClinicalTrials.gov, NCT01942369.
Full text:
1
Collection:
01-internacional
Database:
MEDLINE
Main subject:
Severity of Illness Index
/
Triptorelin Pamoate
/
Endometriosis
/
Luteolytic Agents
Type of study:
Clinical_trials
/
Diagnostic_studies
/
Observational_studies
/
Risk_factors_studies
Limits:
Adult
/
Female
/
Humans
Language:
En
Journal:
Medicine (Baltimore)
Year:
2021
Document type:
Article
Affiliation country:
China